Portfolio Companies
Aldis
Ampulse
BioNanomatrix
BioVigilant
CDI
Endovalve
Hi-G-Tek
ImageTree
Metatomix
NellOne
Nistica
NuPathe
Panomics
Planar Energy Devices
Rajant
RemoteReality
SafeView
SmartSynch
Superprotonic
Sypherlink
 
PORTFOLIO

NuPathe Inc.

NuPathe, Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. The company’s lead product, NP101, is a novel transdermal patch for acute migraine that may address the most common complaints of patients – migraine-associated nausea/vomiting, inconsistent relief, and adverse events.  Phase III clinical trials are being initiated for NP101.  Additionally, NP201, a long acting injectable implant for the treatment of Parkinson’s disease is in preclinical development. General Partner Tracy Warren is a Board observer.

 

Company Web Site
www.nupathe.com